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11 yeara (range 14-74). All had at least one documented episode of spon-
taneous tachycerdia. None had organic heart disease. Twelve pts attributed
the onset of symptoms to exercise or spofi activities. Six of these 12 pts
underwent treadmill exercise test without inducible tachycardia. Durin9 eiec-
trophysiologic studies, all pts demonstrated dual AV nodal physiology, and
10 pte showed inducible 1-2 AV nodal echo beats. These 10 pts underwent
selective RFCA of the slow pathway with successful elimination of the dual
AV nodal physiology. With the mean follow-up (F/U) of 26 + 12 mo (range
3-56 me), none of the 10 pte who received RFCA had recurrencesof symp-
toms (F/U 3-32 me). In the remaining 9 pts without RFCA, 3 pts developed
fachycardia recurrence (F/U 10-56 me); 2of these3 ptaconsequently under-
went RFCA and the other received verapemil with successful control of the
symptoms. We conclude that pts with documented spontaneous techycardia
and the presence of dual AV ncdal physiology without inducible AVNRT are
predominantly male, whose symptoms are often triggered by exercise. Se-
lective RFCAof the slow pathway seems to be beneficial to this group of pts,
especially to those with inducible AV nodal echo beats.
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m983127 ImprovedDefibrillation”Efficacywitha TriadDefibrillationSystemUsinga.9flUFCapacitor
M. Bahu, B.P. Knight, R. Weiss, W. Paladino, S. Hahn, R. Goyal,
E.G. Daoud, M. Hawey, K.C. Man, F. Morady, S.A. Strickberger. University
of Michigan, Ann Arboc Ml, USA
A variety of factors, including defibrillation waveform, electrode configura-
tion, and electrode polarity, may influence the defibrillation efficacy of an
implantable defibrillator (lCD). The routine achievement of lower defibrilla-
tionthresholds mayallowfora reduction in ICDsize, simplitythe implantation
procedure, and improve patient acceptance of this therapy. In this study, the
defibrillation threshold oftwodefibrillation systemswere compared in 26con-
secutive patients. Both systems used a transvenous lead with in-line anodal
and cathodal coils. With the standard system, a biphasic waveform pulse
wee delivered fmm a 125 UFcapacitor. The second system used an identical
biphaaic waveform and lead system as the standard system, but used a 90
UF capacitor, and utilizad the ICD generator “can” as a third electrode. The
standard system had a higher defibrillation threshold (DFT) (10.6 + 5.5 J)
than did the three electrode aystem (8.9 & 6.7 J vs., p = 0.05); however,
the peak voltage was similar between the two systems (361 + 103 V vs.
397 + 123 V, p = 0.07). The atandard system also had higher defibrillation
resistance (49.0 + 9.0 ohms vs 41.4 + 7.3 ohms, p = 0.07) and lower peak
current (7.7 * 2.6 A va. 10.1 * 3.7 A, p < 0.005) than the other system. In
conclusion, the combination of a smaller capacitor reaulting in a shorter dura-
tion waveform with an ICD generator used as athircf electrode is associated
with a 20% lower DFT than observed with a transvenous system alone. The
combination of smaller capacitors and a trial defibrillation system provide for
lower DFT’a and may allow for continued ICD miniaturization.
m983128 FeasibilityandLong-TermOutcomeof ICDImplantationin PatiantsWithLeftVentricular
EjectionFraction<20%
C. Naraeimhan, A. Dhala, S. Deshpande, J. Sra, K. Handa, M.R. Jezayeri,
M. Akhtar. Sinai SamarifarVSt. Luke’s Medical Centers, Milwaukee, W/, USA
Itis generally believed that in patients with severe Ieftventricular dysfunction
(LVEF < 20%), ICD implantation is unlikely to be beneficial because of high
operative mortality and non-arrhythmia cardiac death. However, there is no
data on the feasibility and long-term clinical outcome of ICD implant in this
group of patients. The operative morbidity, mortality (30 daya) and long-term
suwival of patients with ejection fraction <20% (Group 1)were compared
with those with ejection fraction 20-40% (Group Ii). The overall suwival of
both groups were compared using Kaplan-Meier analysis.
Group I (n = 15S) Group II (n =371) P value
Age 62,6 + 11 63.7 + 9.8 “...-
Mile/female S5”A:15% 83%12% ns
Lengthof hospitalstay 8,3 7.5 m
ConcurrentCABG 15.2”A 19.9% ns
Operative morfality o% 0,8% ns
4 vrsurvival 70% 800/. . .,,-
A~p shocks 46% 400/a ns
Conclusion: ICD implantation is feasible with acceptable morbidity and
mortality in patients with very poor left ventricular function. Overall suwival
at 4 yrs was 700/.after ICD implantation in this high risk patient group.
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University Hospita/, Washington, DC, USA
In the Multicenter Automatic Defibrillator Implantation trial (MADIT) a 54%
reduction in mortality was obsewed for post Ml patients (pts) with iow ejection
fractions, nonsustained VT and inducible, nonsuppresaible VT treated with
implantable cardiovertor defibrillator (lCD) as compared to standard medical
therapy. We report an economic evaluation of prophylactic ICDS for this
cohort. Methods: Cost of care and suwival data from the Studies of Left
Ventricular Dysfunction (SOLVD) were analyzed for pta receiving enalapril
for symptomatic congestive heart failure (CHF). Baaed on the MADIT atudy
results, we modeled a new treatment arm with a 54% reduction in mortality
over the SOLVD study period. Lifetime suwival was computed based on a
one-time benefit model (OT), assuming all treatment benefits were obeewed
in the ciinicai trial, and a continuous benefit model (CO), asauming treatment
benefits observed in the clinical trial continued’ throughout the pts lifetime.
Costs of ICD placement, ICD complications, and ICD replacement were
calculated based on Medicare DRG paymenta. Results: Pts who received
enaiaprii incurred a total cost of care of $23,753 and had 5.18 discounted
yeare of survival. Pts who received an ICD incurred CHF related coats of
$29,286 and ICD ralated costs of $46,325 and had 6.55 discounted years of
survival under the OT model. Pts who received an ICO incurred CHF related
costs of $40,844 and iCD related costs of $74,764 and had 9.25 discounted
years of suwival under the CO model. The cost per year of life gained was
$37,652 under the OT model and $22,569 under the CO model. Conclusion:
Based on MADIT, treatment of high risk pta with an ICD would provide
reasonable value for money compared to other accepted medical therapiea.
Further research is needed to refine treatment guidelines forpost-Ml pta, and
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In order to examine whether correlation waveform analysis (CWA) may be
uaedto analyze stored electrograms obtained from implantable defibrfllators,
we studied 25 episodes of monomorphic VT and SR. We aligned beata in
phase and calculated correlation coefficients between SR beats and a SR
template, VT beats and a VTtemplate, and VT beats and a SR template. For
each patient, the 99.5% lower confidence limit for the correlation coefficient
of SR beats vs a SR template was used as a threshold value to discriminate
VT from SR. The correlation coefficient for VT va SR from each episode ia





Uaing this method, we were able to correctly distinguish 23/25 episodes
of monomorphic VT from SR. This is the first demonstration using stored
electrograma that CWA is able to discriminate monomorphic VT from SR
with high sensitivity (92Yo).Such a system may be used for off-line analysis
or real time rhythm detection.
